# A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

> **NCT00758524** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 628 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** LCI699
- **DRUG:** Eplerenone
- **DRUG:** LCI699-matching Placebo
- **DRUG:** Eplerenone-matching Placebo

## Key facts

- **NCT ID:** NCT00758524
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-11
- **Primary completion:** 2009-07-02
- **Final completion:** 2009-07-02
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2021-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00758524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00758524, "A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00758524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*